Cargando…

Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals

Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint c...

Descripción completa

Detalles Bibliográficos
Autores principales: Debaveye, Sam, De Smedt, Delphine, Heirman, Bert, Kavanagh, Shane, Dewulf, Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028282/
https://www.ncbi.nlm.nih.gov/pubmed/32069318
http://dx.doi.org/10.1371/journal.pone.0229235
_version_ 1783498994812452864
author Debaveye, Sam
De Smedt, Delphine
Heirman, Bert
Kavanagh, Shane
Dewulf, Jo
author_facet Debaveye, Sam
De Smedt, Delphine
Heirman, Bert
Kavanagh, Shane
Dewulf, Jo
author_sort Debaveye, Sam
collection PubMed
description Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint concerning one AoP: Human Health. We propose to take this one step further by simultaneously comparing the quantified handprint and footprint on all AoPs through normalization and weighting of the results towards a single score. We discuss two example cases of a pharmaceutical treatment: mebendazole to treat soil-transmitted helminthiases and paliperidone palmitate to treat schizophrenia. Each time, treatment is compared to ‘no treatment’. The footprint of health care is compared to the handprint of improved patient health. The handprint and footprint were normalized separately. To include sensitivity in the normalization step we applied four sets of external normalization factors for both handprint (Global Burden of Disease) and footprint (ReCiPe and PROSUITE). At the weighting step we applied 26 sets of panel weighting factors from three sources. We propose the Relative Sustainability Benefit Rate (RSBR) as a new metric to quantify the relative difference in combined handprint and footprint single score between two alternatives. When only considering the footprint, the first case study is associated with an increased single score burden of treatment compared to ‘no treatment’, while in the second case study treatment reduces the single score burden by 41.1% compared to ‘no treatment’. Also including the handprint provided new insights for the first case study, now showing a decrease of 56.4% in single score burden for treatment compared to ‘no treatment’. For the second case study the reduction of single score burden was confirmed as the handprint burden was also decreased because of treatment by 9.9%, reinforcing the findings.
format Online
Article
Text
id pubmed-7028282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70282822020-02-27 Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals Debaveye, Sam De Smedt, Delphine Heirman, Bert Kavanagh, Shane Dewulf, Jo PLoS One Research Article Life Cycle Assessment typically focuses on the footprint of products and services, expressed on three Areas of Protection (AoP): Human Health, Ecosystems and Resources. While the handprint is often expressed qualitatively, quantified handprints have recently been compared directly to the footprint concerning one AoP: Human Health. We propose to take this one step further by simultaneously comparing the quantified handprint and footprint on all AoPs through normalization and weighting of the results towards a single score. We discuss two example cases of a pharmaceutical treatment: mebendazole to treat soil-transmitted helminthiases and paliperidone palmitate to treat schizophrenia. Each time, treatment is compared to ‘no treatment’. The footprint of health care is compared to the handprint of improved patient health. The handprint and footprint were normalized separately. To include sensitivity in the normalization step we applied four sets of external normalization factors for both handprint (Global Burden of Disease) and footprint (ReCiPe and PROSUITE). At the weighting step we applied 26 sets of panel weighting factors from three sources. We propose the Relative Sustainability Benefit Rate (RSBR) as a new metric to quantify the relative difference in combined handprint and footprint single score between two alternatives. When only considering the footprint, the first case study is associated with an increased single score burden of treatment compared to ‘no treatment’, while in the second case study treatment reduces the single score burden by 41.1% compared to ‘no treatment’. Also including the handprint provided new insights for the first case study, now showing a decrease of 56.4% in single score burden for treatment compared to ‘no treatment’. For the second case study the reduction of single score burden was confirmed as the handprint burden was also decreased because of treatment by 9.9%, reinforcing the findings. Public Library of Science 2020-02-18 /pmc/articles/PMC7028282/ /pubmed/32069318 http://dx.doi.org/10.1371/journal.pone.0229235 Text en © 2020 Debaveye et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Debaveye, Sam
De Smedt, Delphine
Heirman, Bert
Kavanagh, Shane
Dewulf, Jo
Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title_full Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title_fullStr Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title_full_unstemmed Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title_short Quantifying the handprint—Footprint balance into a single score: The example of pharmaceuticals
title_sort quantifying the handprint—footprint balance into a single score: the example of pharmaceuticals
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028282/
https://www.ncbi.nlm.nih.gov/pubmed/32069318
http://dx.doi.org/10.1371/journal.pone.0229235
work_keys_str_mv AT debaveyesam quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT desmedtdelphine quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT heirmanbert quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT kavanaghshane quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals
AT dewulfjo quantifyingthehandprintfootprintbalanceintoasinglescoretheexampleofpharmaceuticals